Calliditas Therapeutics IPO Presentation Deck
Nefecon targets the presumed origin of disease
Drug product based on known active ingredient
Active ingredient is budesonide - an established,
highly potent, locally acting corticosteroid
90% cleared in first pass metabolism by liver →
minimize systemic side effects
Designed to deliver a targeted and highly
concentrated dose of budesonide directly to the
Peyer's patches
calliditas
Liver
Novel targeted release profile
Designed for targeted local delivery of potent
immunosuppressant to Peyer's patches in the ileum
Differentiated release profile
pH-governed delayed disintegration of the
capsule until it reaches the ileum
Potent, sustained exposure throughout the ileum
Budesonide Concentration
Stomach
SEM of Peyer's patches
Duodenum &
Jejunum
lleum
Nefecon
Time
Colon
June 2020
10View entire presentation